Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy

Inclusion Criteria:

Histologic evidence of adenocarcinoma of the prostate deemed candidates for curative RRP
Intermediate or high risk, clinically localized disease
Adequate organ function
Patients must be surgically sterile or must agree to use effective contraception during the period of therapy
Select imaging to rule out metastasis will be done as clinically indicated
Signed and date informed consent document

Exclusion Criteria:

Prior treatment for prostate cancer
Major surgery or radiation therapy within 4 weeks of starting the study treatment
NCI CTCAE grade 3 hemorrhage within 4 weeks of starting therapy
History of or known metastatic prostate cancer
Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
Ongoing cardiac dysrhythmias of NCI CTCAE grade 2 or greater
QTc interval > 500 msec on baseline EKG
Hypertension that cannot be controlled by medications (>150/100 mm Hg despite optimal medical therapy).
Pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication
Known active infection
Concurrent treatment on another clinical trial. Supportive care trials or non-treatment trials, e.g. QOL, are allowed.
Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.